Skip to main content

Table 1 Clinical characteristics of the study participants

From: Identifying genetic variants underlying medication-induced osteonecrosis of the jaw in cancer and osteoporosis: a case control study

 BRONJ total cases (n = 38)BRONJ cancer cases (n = 13)BRONJ osteoporosis cases (n = 25)Normal controls (n = 90)
Age, years79.9 ± 11.760.1 ± 8.776.6 ± 8.841.1 ± 7.2
Males8 (21%)7 (53.8%)2 (8.0%)47 (52.2%)
Diagnosed condition resulting in BP prescription   
 Cancer13 (34.2%)13 (100%)0 (0%) 
  Breast cancer6 (46.2%)6 (46.2%) 
  Multiple myeloma5 (38.5%)5 (38.5%) 
  Prostate cancer2 (15.4%)2 (15.4%) 
 Osteoporosis25 (65.7%)25 (100%) 
BP   
 Zoledronate11 (29.0%)8 (61.5%)3 (12.0%) 
 Alendronate10 (26.0%)10 (40.0%) 
 Residronate5 (13.2%)5 (20.0%) 
 Pamidronate3 (7.9%)3 (23.1%) 
 Ibandronate2 (5.3%)2 (8.0%) 
 Zoledronate/ibandronate1 (2.6%)1 (7.7%) 
 Unknown6 (15.8%)1 (7.7%)5 (20.0%) 
Duration of BP treatment before BRONJ occurrence, months42.7 ± 46.318.1 ± 13.956.0 ± 52.3
  1. Data are mean ± SD or n (%) values